Essential Pharma, an international pharmaceutical generics company dedicated to supplying well-established, “at risk” products to patients across multiple therapeutic areas, announces the appointment of Ingvild Liborg as Chief Executive Officer.
Ingvild, who has a background in Pharmacy, has been at Essential Pharma for more than 10 years, where she started in regulatory affairs before moving on to business development and management.
Over the last four years, Ingvild worked as General Manager and then Deputy CEO of Essential Pharma, as she transitioned into the Chief Executive Officer position. She brings her broad and invaluable experience of the company and the industry to lead EP into a new era as the business is growing and expanding into more geographies in Europe and beyond, while seeking to broaden and deepen relationships with all major stakeholders.
Ingvild Liborg said:
“I am proud to be given the opportunity to lead Essential Pharma at this exciting time as we transition into a fast-growing private equity backed-company with clear goals. Essential Pharma is deeply committed to supporting patients and offering them continued and sustainable access to at-risk generic medicines, and based on our ESG commitments and corporate values, I am confident that as we grow, we will do so responsibly and for the benefit of patients globally.”
Patrick Vink, Chairman of Essential Pharma, said:
“I am pleased that Ingvild has agreed to become Essential Pharma’s CEO. Her 10 years of experience with Essential Pharma and its operations, as well as her industry knowledge, will prove invaluable as the company embarks on a new value-generating growth trajectory.”